CPT code 87269 denotes an immunofluorescent laboratory assay performed to detect Giardia antigens, a targeted parasitology diagnostic used to confirm giardiasis. This code is used nationally across clinical and hospital laboratories and matters for clinical diagnosis, infection control, and public health surveillance where timely, specific parasitic identification alters treatment and containment decisions. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical purpose of the code, expected sites of service, and payer coverage landscape. The publication also presents operational benchmarks relevant to laboratory billing for immunofluorescent parasitology testing, summaries of payer policy themes affecting coverage and prior authorization, and clinical context explaining when immunofluorescent testing for Giardia is typically used versus other diagnostic methods. Data limitations are noted where input fields are not provided. The piece is intended for laboratory managers, billing professionals, and policy analysts needing a focused reference on CPT code 87269 and its role in diagnostic workflows and payer interactions.